Editorial

The mission of Alliance Biosecure Foundation was to promote a fundamental and translational research in biological security. Set up in December 2006 as a Research foundation recognized as of public utility, its mission was to progress the analysis, understanding and management of biological risks linked to current or emerging pathogen agents.

The Alliance BioSecure Foundation has been founded on behalf of industrial companies, involved in biotechnologies and plasma-derived products. Founders are LFB, Baxter, Maco Pharma, STERIS and Albhades Provence, as well as the Etablissement Français du Sang (French Blood Center), the Institut National de la Transfusion Sanguine (French National Institute of Blood Transfusion), and blood donors associations FFDSB & UNDSB. The Alliance BioSecure Research Foundation illustrated also French national politics aimed to encourage industrial investment in fundamental & translational research, in line with European objectives defined by the Lisbon summit (June 2000). Initial capital of the Foundation has hence been granted by the French Ministry of research.

At the end of six years, the Foundation has, thanks to the members of the Executive Board and the Scientific Committee headed by Dr Paul Brown (Bethesda, USA) and Dr Jean-Philippe Deslys (Fontenay-aux-Roses, France), carried out all of the projects foreseen in its initial 5-years plan. It could in 2012 even go beyond making the 5th call for projects on biosafety in the field of prion, this field being defined as the priority field of research for the foundation.

In order to build up on these achievements, the members of the Executive Board have decided unanimously to become a foundation under the aegis of Fondation pour la Recherche Médicale. The Fondation pour la Recherche Medicale had the ability to continue the work of the Foundation, and offered additional expertise with a new Scientific Committee headed by Prof. Sylvain Lehmann (Montpellier University, France) and a guarantee to pursue the scientific excellence of the research projects selected. The resources of the FABS under aegis of FRM were the transfer of the assets of the FABS, around one million Euros, that allowed to set up three more call for projects.

In total, from 2007 to 2015, 8 calls for projects were conducted and the Alliance Biosecure Foundation has financially supported 53 projects in prions research for an overall amount of 3.3 Million Euros. It has covered several fields of prion diseases: Methods of detection, inactivation, elimination, innovative therapies, physiopathology, structural biology, epidemiology, transmission risk assessment and strain typing. We propose here to expose the context and the main results and published data (even those published later but subsequent to the initial work) obtained by the teams that were helped in part by the foundation and we deeply thank Carole Crozet , CR1 INSERM (Research Associate, IRMB, U1183 INSERM, Montpellier, France), who performed this synthesis report.